yakamein
#milfhunter
Anybody on $igld?
Down but about to rebound? Only stock picks
- Thread starter morris
- Start date
Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer.
Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
Our strategy of targeting EPHA2 in conjunction with EPA therapy was shown to be effective through a novel, membrane-based mechanism that controls cell viability. Cell-surface-localized EPHA2 has been implicated in the control of gap junctions and cell plasma membrane polarity, subsequently contributing to tumor migration and invasion 32, 33. Further, EPA, when incorporated into the plasma membrane, can modify lipid rafts, increase membrane compaction, modify intracellular signaling, and inhibit invasive potential 16, 34, 35. Our findings suggest that EPA combined with EPHA2 inhibition drastically increases the polarity, or rigidity, of the plasma membrane through an ABCA1-dependent accumulation of cholesterol and subsequently activates programmed cell death.'
In summary, we have identified a novel combination of EPA with EPHA2 inhibition that displays therapeutic efficacy in TNBC. Our study establishes the rationale for clinical testing of a novel EPA/dasatinib combination therapy in EPHA2-positive TNBC and identifies potential markers of therapeutic response. Excitingly, our EPA-based combination therapy may be applicable to other EphA2-positive cancers that include: aggressive lung cancer, invasive ovarian cancer and metastatic melanoma 47, and warrants further exploration.
^^^^From the same article^^^^
On the stock market today, shares of Amarin (AMRN) jumped 11.6%, to 18.99, in massive volume. Amarin stock is forming a cup with handle base and a buy point at 23.35. The pop in Amarin stock came as biotech companies collectively slipped a fraction.
https://www.investors.com/news/tech...s-priority-review-high-cholesterol-treatment/
Them boys ramping up!
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications | Amarin Corporation plc
https://www.investors.com/news/tech...s-priority-review-high-cholesterol-treatment/
Them boys ramping up!
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications | Amarin Corporation plc
Think about it this way. At the moment, it is estimated that more than 35 million Americans or more than 10% of the United States population are using statin-based treatments. A large percentage of these see persistent high cholesterol levels.
In the past, the American Heart Association recommended the use of baby aspirin to control risk of cardiovascular events in this population. However, the AHA has pulled its recommendation. Moreover, there are absolutely no treatments on the market with this indication, leading to a vast medical need.
Considering everything that Vascepa has going for it, should the sNDA be approved, AMRN could be sitting on a blockbuster drug that is quickly adopted by the high cardiovascular risk community in the United States and around the world.
Amarin (AMRN) Stock: A Blockbuster In The Making | Alpha Stock News
In the past, the American Heart Association recommended the use of baby aspirin to control risk of cardiovascular events in this population. However, the AHA has pulled its recommendation. Moreover, there are absolutely no treatments on the market with this indication, leading to a vast medical need.
Considering everything that Vascepa has going for it, should the sNDA be approved, AMRN could be sitting on a blockbuster drug that is quickly adopted by the high cardiovascular risk community in the United States and around the world.
Amarin (AMRN) Stock: A Blockbuster In The Making | Alpha Stock News
"The distinction of the cardiovascular benefits observed in REDUCE-IT and JELIS from the lack of cardiovascular benefits observed in statin-treated populations with add-on omega-3 fatty acid mixtures is likely due specifically to the high eicosapentaenoic acid (EPA) levels. EPA has unique lipid and lipoprotein, anti-inflammatory, antiplatelet, antithrombotic, and cellular modifying effects, all of which may contribute to benefits in atherosclerotic processes such as reduced development, slowed progression, and increased stabilization of atherosclerotic plaque (19,54–56)."
To my bio-tech stock thread brehs.
Liquidated the rest of my PRPO position. Made (guessing) 15-20%. Bot lord the unrealized gains I lost
.
Was able to swing both YRIV and AMR today for 7%. (Woke yo so damn late smh).
Holding YRIV throughly tmmrw’s court hearing (small position).
Still eyeing NVUS and PES.
Liquidated the rest of my PRPO position. Made (guessing) 15-20%. Bot lord the unrealized gains I lost
.Was able to swing both YRIV and AMR today for 7%. (Woke yo so damn late smh).
Holding YRIV throughly tmmrw’s court hearing (small position).
Still eyeing NVUS and PES.
Iceson Beckford
Rich In Spirit.
Wouldnt this be a great day for me to get my first stocks
So far I’ve invested in:
Phillip Morris(2 Shares)
Ford (12 Shares)
Amarin (2 Shares)
Diageo (1 Share)
Bayer AG (2 Shares)
Nothing special but tried to diversify without investing in areas I have no knowledge in.
Any Thoughts/Tips?
Last edited:
Looks like you went after some high paying dividend stock except for AMRN.
Nothing wrong with Dividends at all.
W/O knowing other reasons as to why you picked each stock, I only question the Diageo pick. Pretty Expensive compared to the other stocks in your portfolio.
Im not an expert by any means, but if this was an portfolio given to me to have for my self, Id prolly sell Diageo to spread that cash around to other stocks. AMRN and 1 other one.
But, like I said:
1. Im no expert.
2. I don't know why you chose each stock.
For all I know, you could be expecting a good news release that's gonna result in to 10-20% jump in Diageo.
GL 2 U
Iceson Beckford
Rich In Spirit.
Thanks for the response breh.
Honestly I just tried to pick stock that I know has some long term appeal across various sectors.
In regards to Diageo, I picked it because I personally drink Henny,Ciroc and Smirnoff. People love alcohol and I know they own a lot of the prominent brands.
However it is quite pricey. Id rather get my hands on some Nike Stock even though as I type this it seems to be my best performing stock.
Looks like Ill scoop some up another time if anything.